Pubblicazioni

Modulating undruggable targets to overcome cancer therapy resistance

2022 - DRUG RESISTANCE UPDATES

Passirani, C.; Vessieres, A.; La Regina, G.; Link, W.; Silvestri, R.

Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper

2016 - EUROPEAN JOURNAL OF HAEMATOLOGY

Zinzani, Pier Luigi; Corradini, Paolo; Martelli, Maurizio; Minotti, Giorgio; Oliva, Stefano; Spina, Michele; Barosi, Giovanni; Tura, Sante

An overview of early investigational therapies for chemoresistant ovarian cancer

2015 - EXPERT OPINION ON INVESTIGATIONAL DRUGS

Marchetti, Claudia; Ledermann, Jonathan A.; BENEDETTI PANICI, Pierluigi

ErbB-3 activation by NRG-1Î² sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs)

2015 - ONCOTARGET

Prasetyanti, Pramudita R.; Capone, Emily; Barcaroli, Daniela; D'Agostino, Daniela; Volpe, Silvia; Benfante, Antonina; van Hooff, Sander; Iacobelli, Valentina; Rossi, Cosmo; Iacobelli, Stefano; Medema, Jan Paul; de Laurenzi, Vincenzo; Sala, Gianluca